Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced recently that it has augmented its executive management team with the addition of Jean M. Franchi as the new Chief Financial Officer (CFO) effective August 21, 2017. Ms. Franchi will take up the role of planning and overseeing the overall financial activities of the company to significantly support the continuous advancement of various pre-clinical and clinical product candidates for cancer conditions.
Previously, Ms. Franchi has held several senior financial management roles in various leading companies in biotechnology and life science sectors. According to Richard peters, the president and CEO of Merrimack, Ms. Franchi is coming to Merrimack with extensive experience in managing corporate finance and will support the development of strong public awareness for the ongoing clinical development strategies.
With the latest leadership additions, Merrimack is certain that they have strengthened the executive team that will help them deliver their promises of addressing cancer-related problems. Ms. Franchi is excited to take up the new position and she passionately pledged to deliver the first-class and accurate solutions for cancer.
Ms. Franchi has a Bachelor’s degree in Business Administration from Hofstra University and before joining Merrimack, she served in the capacity of CFO in Dimension Therapeutics where she managed all the financial activities including the firm’s initial public offering. She also worked at Good Start Genetics as the company CFO and Sanofi Genzyme where she spent about 16 years as the vice president of the Corporate Finance department.
Merrimack recently announced their financial results for the second quarter and the key expansions to the executive team and clinical developments have significantly strengthened the company’s financial and clinical strategy. With a wealthy, biomarker-driven research and development projects underway, including the essential data expected next year and capable preclinical programs, the company is well positioned to meet and exceed their goals.
Other additions to the executive team include the appointments of Dr. Sergio Santillana as the chief medical officer, Ellen Forest as the Head of Human Resources, and Thomas Needham as the chief business officer.
